The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Gray matter atrophy is related to long‐term disability in multiple sclerosis
Abstract
Objective: To determine the relation of gray matter (GM) and white matter (WM) brain volumes, and WM lesion load, with clinical outcomes 20 years after first presentation with clinically isolated syndrome suggestive of multiple sclerosis (MS). Methods: Seventy‐three patients were studied a mean of 20 years from first presentation with a clinically isolated syndrome (33 of whom developed relapsing‐remitting MS and 11 secondary‐progressive MS, with the rest experiencing no further definite neurological events), together with 25 healthy control subjects. GM and WM volumetric measures were obtained from three‐dimensional T1‐weighted brain magnetic resonance images using Statistical Parametric Mapping 2. Results: Significant GM (p < 0.001) and WM atrophy (p = 0.001) was seen in MS patients compared with control subjects. There was significantly more GM, but not WM atrophy, in secondary‐progressive MS versus relapsing‐remitting MS (p = 0.003), and relapsing‐remitting MS versus clinically isolated syndrome (p < 0.001). GM, but not WM, fraction correlated with expanded disability status scale (rs = −0.48; p < 0.001) and MS Functional Composite scores (rs = 0.59; p < 0.001). WM lesion load correlated with GM (rs = −0.63; p < 0.001), but not with WM fraction. Regression modeling indicated that the GM fraction explained more of the variability in clinical measures than did WM lesion load. Interpretation: In MS patients with a relatively long and homogeneous disease duration, GM atrophy is more marked than WM atrophy, and reflects disease subtype and disability to a greater extent than WM atrophy or lesions. Ann Neurol 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Self-citationDiagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Self-citationAxonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis
Smith, S. M., Zhang, Y., Jenkinson, M., Chen, J., Matthews, P. M., Federico, A., & De Stefano, N. (2002) · NeuroImage · doi:10.1006/nimg.2002.1040 · Cited by 2,013
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 1×
“One such explanation might be that GM demyelinating lesions, although not visible on conventional MRI, are commonly found at autopsy.(35,36) Our findings emphasize that further research to elucidate pathogenic mechanisms in MS should focus on GM as well as WM pathology.”
BackgroundFischer, J. S., Rudick, R. A., Cutter, G. R., Reingold, S. C., & National MS Society Clinical Outcomes Assessment Task Force (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 993
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Self-citation
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Howell, O. W., Reeves, C. A., Nicholas, R., Carassiti, D., Radotra, B., Gentleman, S. M., Serafini, B., Aloisi, F., Roncaroli, F., Magliozzi, R., et al. (2011) · Brain · doi:10.1093/brain/awr182 · Cited by 858
Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis
Trapp, B. D., & Stys, P. K. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70043-2 · Cited by 621
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Silent progression in disease activity–free relapsing multiple sclerosis
University of California, S. F. M. T., Cree, B. A. C., Hollenbach, J. A., Bove, R., Kirkish, G., Sacco, S., Caverzasi, E., Bischof, A., Gundel, T., Zhu, A. H., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25463 · Cited by 465
He, Y., Dagher, A., Chen, Z., Charil, A., Zijdenbos, A., Worsley, K., & Evans, A. (2009) · Brain · doi:10.1093/brain/awp089 · Cited by 452
Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Choi, S. R., Howell, O. W., Carassiti, D., Magliozzi, R., Gveric, D., Muraro, P. A., Nicholas, R., Roncaroli, F., & Reynolds, R. (2012) · Brain · doi:10.1093/brain/aws189 · Cited by 386
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis
Campbell, G. R., Ziabreva, I., Reeve, A. K., Krishnan, K. J., Reynolds, R., Howell, O., Lassmann, H., Turnbull, D. M., & Mahad, D. J. (2011) · Annals of Neurology · doi:10.1002/ana.22109 · Cited by 386
Progression of regional grey matter atrophy in multiple sclerosis
Eshaghi, A., Marinescu, R. V., Young, A. L., Firth, N. C., Prados, F., Jorge Cardoso, M., Tur, C., De Angelis, F., Cawley, N., Brownlee, W. J., et al. (2018) · Brain · doi:10.1093/brain/awy088 · Cited by 372
Self-citationEpidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Clinical Relevance of Brain Volume Measures in Multiple Sclerosis
De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 301
Inflammatory intrathecal profiles and cortical damage in multiple sclerosis
Magliozzi, R., Howell, O. W., Nicholas, R., Cruciani, C., Castellaro, M., Romualdi, C., Rossi, S., Pitteri, M., Benedetti, M. D., Gajofatto, A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25197 · Cited by 298
Measurement and clinical effect of grey matter pathology in multiple sclerosis
Geurts, J. J., Calabrese, M., Fisher, E., & Rudick, R. A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70230-2 · Cited by 298
Ganglion Cell Loss in Relation to Visual Disability in Multiple Sclerosis
Walter, S. D., Ishikawa, H., Galetta, K. M., Sakai, R. E., Feller, D. J., Henderson, S. B., Wilson, J. A., Maguire, M. G., Galetta, S. L., Frohman, E., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.11.032 · Cited by 294
Onset of secondary progressive phase and long-term evolution of multiple sclerosis
Scalfari, A., Neuhaus, A., Daumer, M., Muraro, P. A., & Ebers, G. C. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-304333 · Cited by 291
Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant
Steenwijk, M. D., Geurts, J. J. G., Daams, M., Tijms, B. M., Wink, A. M., Balk, L. J., Tewarie, P. K., Uitdehaag, B. M. J., Barkhof, F., Vrenken, H., et al. (2016) · Brain · doi:10.1093/brain/awv337 · Cited by 281
Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis
Witte, M. E., Mahad, D. J., Lassmann, H., & van Horssen, J. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.11.007 · Cited by 278
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Chard, D. T., Jackson, J. S., Miller, D. H., & Wheeler‐Kingshott, C. A. M. (2010) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22214 · Cited by 257
Self-citationBurkholder, B. M., Osborne, B., Loguidice, M. J., Bisker, E., Frohman, T. C., Conger, A., Ratchford, J. N., Warner, C., Markowitz, C. E., Jacobs, D. A., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.230 · Cited by 199
Jürgens, T., Jafari, M., Kreutzfeldt, M., Bahn, E., Brück, W., Kerschensteiner, M., & Merkler, D. (2016) · Brain · doi:10.1093/brain/awv353 · Cited by 175
Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis
Correale, J., Marrodan, M., & Ysrraelit, M. C. (2019) · Biomedicines · doi:10.3390/biomedicines7010014 · Cited by 167
Trapp, B. D., Vignos, M., Dudman, J., Chang, A., Fisher, E., Staugaitis, S. M., Battapady, H., Mork, S., Ontaneda, D., Jones, S. E., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30245-x · Cited by 146
Baxi, E. G., DeBruin, J., Jin, J., Strasburger, H. J., Smith, M. D., Orthmann‐Murphy, J. L., Schott, J. T., Fairchild, A. N., Bergles, D. E., & Calabresi, P. A. (2017) · Glia · doi:10.1002/glia.23229 · Cited by 97
Bellizzi, M. J., Geathers, J. S., Allan, K. C., & Gelbard, H. A. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1171-15.2016 · Cited by 41
“Gray matter degeneration contributes to chronic disability and cognitive impairment in patients with multiple sclerosis (MS), and progresses despite current treatments (Amato et al., 2004; Fisniku et al., 2008; Rudick et al., 2009).”
BackgroundTen years of proteomics in multiple sclerosis
Farias, A. S., Pradella, F., Schmitt, A., Santos, L. M. B., & Martins‐de‐Souza, D. (2014) · PROTEOMICS · doi:10.1002/pmic.201300268 · Cited by 40
Scalabrino, G. (2022) · Biomedicines · doi:10.3390/biomedicines10040815 · Cited by 10
Metadata
- Authors
- Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., & Miller, D. H.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2008-06-20
- Volume
- 64
- Issue
- 3
- Pages
- 247-254
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2013370381
- Cited by
- 500
- References
- 39
- FWCI
- 20.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.